TEMPEST THERAPEUTICS, INC.

Consensus Tempest Therapeutics, Inc.

Stocks

TPST

US87978U2078

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 18:08:43 31/08/2026 +04			5-day change	1st Jan Change
1.085 ^USD	+2.36%		-2.27%	-62.54%

08-25	Tempest Therapeutics, Inc. Appoints Nicholas Rossettos as Chief Financial Officer, Effective September 1, 2026	CI
08-25	Tempest Therapeutics, Inc. Announces Executive Changes, Effective September 1, 2026	CI

Evolution of the Average Target: Tempest Therapeutics, Inc.

Evolution of the Target Price: Tempest Therapeutics, Inc.

Changes in Analyst Recommendations: Tempest Therapeutics, Inc.

487341455216e9cf79100ef7de7e14.nUtHwKnh5lf-sNPXd9WqV55BYWad1xL8Kctzm2JmWO4.xzkRmdyXoifNg7vnJ4HQB8EDVDTMtVudXLkX8C4kAoH7AD-h6JiSApn-vA~185e75528e82b4ec1b152d94fc40140e

Analysts' recommendations: Tempest Therapeutics, Inc.

01-22	HC Wainwright Upgrades Tempest Therapeutics to Buy From Neutral, Price Target is $11	MT
10/04/25	HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy	MT
14/03/24	Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	MT
11/10/23	HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	MT
23/03/23	Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	MT
15/09/22	Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	MT
13/05/22	HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	MT
28/04/22	Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	MT
21/10/21	Tempest Therapeutics : William Blair Initiates Tempest Therapeutics at Outperform Rating	MT
13/07/21	Tempest Therapeutics : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	MT
06/07/21	Tempest Therapeutics : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPEST THERAPEUTICS, INC.			-	-	+937.74%
	LONZA GROUP AG					+16.67%
	REVOLUTION MEDICINES, INC.					+18.87%
	IQVIA HOLDINGS INC.					+5.13%
	BEONE MEDICINES AG					+17.84%
	CELLTRION, INC.					+39.5%
	MEDPACE HOLDINGS, INC.					-3.13%
	ASCENDIS PHARMA A/S					+27.58%
	EUROFINS SCIENTIFIC SE					+0.23%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-3.6%
	Average					+105.68%
	Weighted average by Cap.					+15.75%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

1.060USD

Average target price

11.00USD

Spread / Average Target

+937.74%

High Price Target

11.00USD

Spread / Highest target

+937.74%

Low Price Target

11.00USD

Spread / Lowest Target

+937.74%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
TPST Stock
Consensus Tempest Therapeutics, Inc.

The best tools reserved for subscribers to boost the performance of your investments!